Funder: Bill & Melinda Gates Foundation
Due Dates: January 31, 2025 (Option A) | May 31, 2025 (Option B)
Funding Amounts: Up to $750,000 per project (Option A, up to 18 months) | Option B: funding and duration negotiable, based on project scope
Summary: Supports innovative manufacturing platforms to produce monoclonal antibodies at $10/gram for global health applications, with two tracks for early-stage and advanced concepts.
Key Information: Applicants may only apply to one option (A or B), not both.